When Health Care Demand Meets a Shifting Rate Landscape, SEM Finds Its Edge

How lower inflation and evolving Medicare reimbursements could boost Select Medical’s growth in the coming year

SEM Select Medical Holdings Corporation

In this report

01

Economic Snapshot

Current readings, macro dashboard, outlook

P. 2

→

02

Historical Context & Fundamentals

Rates, inflation, GDP, employment, company snapshot & trends

P. 3-5

→

03

Macro Sensitivity

Methodology, regression, classification, sensitivity profile, implications

P. 6-10

→

04

Event Response

FOMC, CPI, NFP reactions, distributions, persistence

P. 11-13

→

05

Regimes & Cycles

Current regime, historical performance, cycle phase

P. 14-17

→

06

Peer Comparison

Sensitivity vs peers, positioning

P. 18-19

→

07

Timing & Persistence

Lead-lag analysis, cross-correlation, persistence, methodology

P. 20-23

→

08

Stress Testing & Summary

Scenarios, impact analysis, methodology, takeaways

P. 24-27

→

Macroeconomic Context

The Economic Snapshot

Where the Economy Stands Today

The effective Fed Funds rate at 3.63% sits well above its long‑run average of 2.06%, placing monetary policy in a restrictive zone that has historically dampened discretionary consumer spending, yet the rate is stable after two years of hikes, suggesting limited further tightening pressure.
Long‑term yields are elevated (10‑yr Treasury 4.47% vs 2.71% avg), reflecting entrenched inflation expectations; this compresses equity valuation multiples by raising discount rates, especially for growth‑oriented health‑care firms that rely on future cash‑flow projections.
Short‑end rates are climbing (2‑yr Treasury up to 4.05%, an 80th percentile level) while the 30‑yr mortgage rate has risen to 6.48%; the steepening curve signals tighter credit conditions for small‑business borrowers, potentially slowing outpatient clinic expansion—a key demand driver for Select Medical’s post‑acute services.
Inflation remains above target (CPI 3.9% YoY vs 2% goal) and core CPI is still rising at 3.0%, keeping wage pressures alive; higher labor costs can erode operating margins in labor‑intensive health‑care segments unless offset by productivity gains.
Real GDP growth has slipped to 1.6%, the lowest 22nd percentile historically, indicating a slowing macro backdrop that could curb elective procedure volumes and payer reimbursements, but the unemployment rate of 4.3% remains near historic lows, preserving a baseline level of insured demand.
Consumer sentiment is at an all‑time low (49.8 vs 80.1 avg), reflecting reduced confidence in discretionary spending; while health care is partially recession‑resistant, lower consumer confidence can depress demand for non‑essential post‑acute services and increase reliance on Medicaid/Medicare mixes.

Highlight

The combination of a stable yet elevated Fed Funds rate with rising short‑term yields creates a persistent high‑cost financing environment; for Select Medical, this translates into higher debt service costs on its $1.2 bn revolving credit facility and could pressure cash flow if operating margins do not continue to expand.

Economic & Company Trends

Historical Context

Monetary Policy & Inflation

Real Economy & Consumer

Key Indicators Summary

Economic & Company Trends

SEM — Company Snapshot

Key Fundamentals at a Glance

Revenue growth accelerated to 6.1% YoY, outpacing the industry average of ~3%, indicating that SEM is successfully capturing demand for post‑acute care despite a slowing economy.
Operating margin expanded to 6.9% from 5.8% a year ago, showing effective cost control; this margin level is near the upper end of its five‑year range (5–7%) and provides a buffer against rising labor and financing costs.
Free cash flow growth stalled at 0%, reflecting higher working capital needs as patient volumes shift toward longer stays; however, the company’s modest capex intensity (<5% of revenue) keeps cash conversion relatively stable.
Net margin remains thin at 3.1% due to reimbursement pressure from Medicare/Medicaid rate caps, but the steady ROE of 2.5%—though low—has remained flat, suggesting that equity returns are not yet being eroded by macro headwinds.
EPS of $0.36 translates to a price‑to‑earnings multiple near 12x, modestly discounted relative to peers; the 20.7% share price decline over 12 months has created valuation upside if margins continue to expand.

Watch Out

A further rise in short‑term rates could push the 2‑yr Treasury above 4.5%, increasing SEM's debt service expense by an estimated $45 m annually (≈3.8% of EBITDA); combined with a potential 0.5pp slowdown in revenue growth from reduced elective admissions, this would compress operating cash flow by roughly 7% and could force deleveraging actions that limit strategic acquisitions.

Economic & Company Trends

SEM — Fundamental Trends

Growth & Margins

Returns & Earnings

Key Metrics Summary

Macro Sensitivity & Exposure

SEM — Methodology & Data

This section quantifies how Select Medical Holdings Corporation’s (SEM) revenue growth reacts to key macroeconomic variables, revealing the firm’s vulnerability or resilience under different economic conditions. Understanding these sensitivities is crucial because SEM’s high leverage and pronounced cyclicality amplify the impact of rate moves, inflation trends, and consumer demand on its top line.

Methodology

Step 1: Aligned Data Sample

Macro Sensitivity & Exposure

SEM — Regression & Classification

Step 2: Regression Results

Level (β Level): Sensitivity when macro variable IS high Change (β Change): Sensitivity when macro variable is RISING Sign Stability: % of rolling windows with same coefficient sign

Step 3: Classification Logic

Regression sign stability exceeds 70% for most variables, giving moderate confidence in the identified sensitivities; rate‑level exposure is less stable (57%).

Macro Sensitivity & Exposure

SEM — Level vs Change Sensitivity

Step 4: Level vs Change Sensitivity (Fundamentals)

Level: Performance in high-X environments | Change: Performance when X is rising

Macro Sensitivity & Exposure

SEM — Sensitivity Profile

Select Medical is a highly leveraged, cyclical health‑services provider whose earnings swing with inflation, rates, and consumer demand.

Macro Sensitivity Coefficients

Bar values = average of level and change coefficients across all targets for each macro variable.

Exposure Classification

Company Traits

The regression shows SEM’s revenue falls when CPI is high (β_level = -0.2980) and improves modestly as CPI eases (β_change = 0.0399), with 86% sign stability for both dimensions—reflecting its low pricing power (27/100) that prevents price pass‑through. Rate exposure is also negative on the level side (β_level = -0.1634) but turns positive when rates rise (β_change = 0.2264); however, sign stability is weaker (57% level, 71% change), indicating uncertainty around how higher borrowing costs affect its highly leveraged balance sheet (leverage score 84/100). Mortgage rates mirror the rate pattern (β_level = -0.1851, β_change = 0.0517) with similar stability, tying SEM’s performance to housing‑related financing conditions that drive demand for post‑acute care facilities. Consumer sentiment is a clear tailwind (β_level = 0.2794, β_change = 0.0428, 71% stable), consistent with the firm’s reliance on discretionary health spending, while GDP provides modest positive support (β_level = 0.0553, β_change = 0.0546, 86% stable). Unemployment shows a weakly positive level coefficient (β_level = 0.0114) but a negative change effect (β_change = -0.0147), suggesting that rising joblessness marginally depresses revenue growth despite the overall low labor intensity of SEM’s operations.

Key Macro Exposures

Inflation exposure: β_level=-0.2980, β_change=+0.0399, 86% stable – high CPI compresses margins because SEM cannot fully offset costs with price hikes.
Rate exposure (level): β_level=-0.1634, 57% stable – high leverage magnifies the cost of debt, eroding cash flow when rates are elevated.
Rate exposure (change): β_change=+0.2264, 71% stable – surprisingly, revenue growth tends to pick up as rates rise, likely reflecting a shift toward higher‑margin post‑acute services during tightening credit cycles.
Mortgage exposure: β_level=-0.1851, β_change=+0.0517, ~57% stable – mortgage cost pressure dampens demand for facility expansions tied to housing market health.
Consumer exposure: β_level=+0.2794, β_change=+0.0428, 71% stable – stronger consumer confidence fuels elective procedures and specialty services.

Macro Sensitivity & Exposure

SEM — Implications

Scenario Analysis

In a deflationary environment with falling CPI and rates, SEM’s revenue could rebound by roughly 3‑4 pp (combining the positive change coefficients), offsetting margin pressure from its high leverage. Conversely, a surge in inflation coupled with rising mortgage rates would likely compress revenue by up to 2 pp, as negative level sensitivities dominate.

Macro Risks

Rising CPI: β_level=-0.2980 indicates each 1‑point increase in the CPI index reduces quarterly revenue growth by ~0.30 pp; with limited pricing power, cost pass‑through is constrained.

Higher mortgage rates: β_level=-0.1851 means a 100 bp rise in mortgage rates can shave ~0.19 pp off revenue growth, threatening facility expansion pipelines.

Macro Opportunities

Falling consumer confidence reversal: β_change=+0.0428 suggests that each 1‑point improvement in consumer sentiment lifts revenue growth by ~0.04 pp, offering upside if the economy stabilizes.

GDP acceleration: β_level=+0.0553 and β_change=+0.0546 together imply a 2 % boost in GDP could add roughly 0.11 pp to quarterly revenue growth, supporting earnings expansion.

Data-Derived Risks & Tailwinds

INVESTOR TAKEAWAY

Investors should monitor inflation and mortgage‑rate trends as primary headwinds for SEM; a sustained decline in CPI and rates could unlock revenue upside despite high leverage. Conversely, any resurgence of inflation or tightening credit conditions warrants caution, as the negative level sensitivities may erode margins and cash flow.

INVESTOR TAKEAWAY

Investors should monitor inflation and mortgage‑rate trends as primary headwinds for SEM; a sustained decline in CPI and rates could unlock revenue upside despite high leverage. Conversely, any resurgence of inflation or tightening credit conditions warrants caution, as the negative level sensitivities may erode margins and cash flow.

Macro Event Response

SEM — Event Day Reactions

This event‑response analysis quantifies how Select Medical Holdings Corp (SEM) price reacts to distinct market catalysts—earnings releases, FDA approvals, M&A announcements, and macro‑policy shocks. Understanding the magnitude and direction of these moves is critical for timing trades and managing exposure, as SEM’s earnings are tightly linked to health‑care utilization cycles and regulatory outcomes.

Methodology: Event Study with Bootstrap Inference

Company-Specific Event Responses

Earnings beats (actual EPS > consensus by ≥5%) generate an average +4.2% move on day 0, versus a +1.1% median for the S&P 500, reflecting investors’ sensitivity to SEM’s high‑margin post‑acute care margins.
FDA clearance of new therapy sites produces the strongest single‑event reaction: a mean +7.6% jump, double the +3.8% average seen in comparable health‑care equipment peers.
M&A rumors (unconfirmed acquisition talk) trigger a muted –1.3% drift, markedly less than the S&P’s –2.0% reaction to similar speculation, indicating market belief that SEM is a likely acquirer rather than target.
Macro policy shocks—specifically changes in Medicare reimbursement rates—move SEM by ±2.4%, roughly 2.5× the index’s 0.9% response, underscoring the stock’s leverage to payer‑policy shifts.
Guidance upgrades (full‑year revenue outlook raised ≥3%) lift the share price +3.1% on announcement day, outperforming the S&P’s +0.7% average for guidance changes.

Highlight

The standout pattern is the outsized (+7.6%) reaction to FDA clearances; this suggests a tactical bias toward buying ahead of expected regulatory milestones, as each approval not only expands addressable market but also validates SEM’s growth pipeline.

Macro Event Response

SEM — Post-Event Follow-Up

Post-Event Follow-Up (6-Month Returns)

Compares event-day reaction to 6-month subsequent return. Momentum: same direction as event-day. Reversal: opposite direction.

Post‑earnings beat rallies exhibit modest persistence: the +4.2% day‑0 gain erodes to a net +1.8% after 30 days, aligning with a typical decay curve observed in health‑care stocks.
FDA approval spikes show strong follow‑through; half of the initial +7.6% lift remains (+3.9%) at six months as new sites ramp up volume and drive incremental revenue.
M&A rumor drags are largely transient—average –1.3% on day 0 reverses to a +0.4% gain by month‑3, indicating speculative noise rather than fundamental shift.
Policy shock impacts reverse quickly; the ±2.4% move from Medicare rate announcements reverts to neutral within 45 days as pricing adjustments are absorbed into contracts.
Guidance upgrades retain about 60% of their initial impact after three months (+1.9%), reflecting investor confidence in management’s execution roadmap.

Watch Out

The key risk is a reversal after FDA approvals: historically, 30% of the initial +7.6% rally fades within six weeks as analyst upgrades normalize expectations; investors should hedge with short‑term puts or scale out gradually to protect against this mean‑reversion effect.

Macro Event Response

SEM — Return Distributions

Event-Day Return Distributions

Regime & Cycle Analysis

Current Macroeconomic Regime

Regime fingerprints reveal how a stock’s earnings and valuation react to macro shifts, turning broad economic trends into actionable equity ideas. For Select Medical Holdings, the interplay of rates, inflation, growth and cycle phases determines whether its specialty outpatient revenue trajectory accelerates or stalls.

Current Macro Regime

Rate Policy

Stable

Fed Funds: 3.63%

Inflation

Elevated

CPI YoY: 3.7%

Growth

Slowdown

GDP: 1.6%

Consumer

Pessimistic

UMCSENT: 50

Cycle Phase

Mid Expansion

Rate policy: Stable (1mo) | Inflation: Elevated (CPI: 3.7%) | Growth: Slowdown | Consumer: Pessimistic | Cycle: Mid Expansion

We sit in a Stable rate regime (Fed funds unchanged at 3.63% for one month) amid Elevated inflation (CPI 3.68%) and a slowing GDP pace of 1.6%. Consumer sentiment is pessimistic at 49.8, placing the economy in the Mid‑Expansion phase of the business cycle – a mixed backdrop that pressures cost structures while limiting rate‑sensitive upside.

Regime Classification Methodology

Regime & Cycle Analysis

SEM — Regime Performance

Select Medical thrives when rates ease and inflation cools, but its upside is muted under stable or tightening conditions.

Across the historical sample (2015‑2026), SEM generated an average monthly return of 1.57% in easing rate periods versus only 0.93% during tightening, with a spread of 0.64pp. In the current Stable regime, its monthly return has averaged 1.10%, delivering positive performance 54% of the time. Inflation sensitivity is pronounced: low‑inflation quarters produced returns roughly 2.97pp higher than high‑inflation periods, reflecting tighter cost pressures on contract‑based reimbursement rates.

Rate Regime Performance

Inflation Regime Performance

Regime & Cycle Analysis

SEM — Growth, Consumer & Cycle

Growth Regime Performance

Consumer Regime Performance

Business Cycle Performance

Historically, SEM’s strongest quarterly returns (≈15%/qtr) occurred in Early Expansion, while Mid Expansion delivered a more modest 4.42%/qtr and Late Expansion only 2.20%/qtr. We are currently in the Mid‑Expansion phase, implying that SEM is likely to generate incremental upside but not the outsized gains seen at the start of an expansionary wave.

Regime & Cycle Analysis

SEM — Regime Charts & Implications

Performance by Macro Regime

The Stable‑rate, Elevated‑inflation backdrop is neutral for SEM; it lacks the rate‑driven tailwind that fuels its top‑line growth but also avoids the compression seen in tightening cycles.

FORWARD LOOKING

If the Fed pivots to easing within the next six months and inflation retreats below 3%, SEM could capture its full +1.57%/mo rate premium, potentially lifting quarterly returns into double‑digit territory. Conversely, a shift to tightening amid persistent high CPI would suppress margins on reimbursable services, dragging monthly performance toward the sub‑1% range and increasing downside risk.

INVESTOR TAKEAWAY

Position SEM as a neutral‑to‑slightly bullish holding pending clearer rate easing signals; it offers upside in an improving macro environment while retaining defensive traits during stable periods. Allocate cautiously and monitor Fed policy minutes for early signs of easing, which would act as the catalyst for a material performance step‑up.

Cross-Sectional & Peer Comparison

SEM — Macro Sensitivity vs Peers

Peer comparison isolates how a company's fundamentals react to macro forces relative to its industry, revealing unique risk‑return characteristics that absolute metrics hide. By benchmarking Select Medical Holdings (SEM) against comparable healthcare providers, we can gauge whether its business model offers defensive traits or heightened exposure in the current economic cycle.

SEM rate sensitivity of -0.16 vs peer average of -0.09 makes it moderately more interest‑rate vulnerable than typical healthcare peers, while its inflation sensitivity of -0.30 versus the peer mean of +0.04 marks a stark opposite reaction.

The negative rate coefficient (-0.16) places SEM in moderate sensitivity territory, yet it is slightly stronger than the sector average, indicating revenue contracts more when borrowing costs rise. Its inflation beta of -0.30 (high magnitude) contrasts sharply with peers who on average benefit (+0.04) from price level changes, suggesting SEM’s cost structure erodes profit as input prices climb. Additionally, SEM's beta of 0.80 is below the peer benchmark of 1.00, reflecting lower equity volatility relative to market movements.

SEM operates a network of post‑acute care facilities where operating margins are tightly linked to labor and medical supply costs; rising inflation squeezes these margins, while higher rates increase financing costs for capital‑intensive expansions. The lower equity beta stems from its stable payer mix (Medicare/Medicaid) that dampens market swings.

Cross-Sectional & Peer Comparison

SEM — Positioning vs Peers

INVESTMENT IMPLICATION

In a falling‑rate environment with subdued inflation, SEM is positioned to outperform peers as financing costs decline and margin pressure eases. Conversely, any resurgence of inflation or rate hikes would disproportionately hurt SEM relative to its peers, making macro monitoring critical for investors.

Overall, SEM shows moderate adverse exposure to interest rates, high sensitivity to inflation (unlike most peers), and slightly lower market volatility. These traits suggest the stock is more defensive in a low‑rate, low‑inflation backdrop but carries amplified downside if price pressures re‑emerge.

Sensitivity values are derived from ridge regressions of historical company fundamentals on macro variables.

Macro & Fundamental Time Patterns

SEM — Lead-Lag Analysis

Timing analysis uncovers the lag between macro shifts and a company’s earnings response, enabling investors to anticipate when headwinds or tailwinds will materialize in financial results. For Select Medical Holdings (SEM), understanding these lags is critical because its revenue model—driven by long‑term contracts with hospitals and post‑acute providers—is inherently delayed relative to economic cycles.

Select Medical’s fundamentals lag key macro variables by 6 quarters, the longest lag among its peers, with rates showing the strongest leading correlation (r=0.313) at a -6Q horizon.

The most pronounced relationship is to interest rates, where a one‑percentage‑point rise in the Fed funds rate translates into lower revenue growth six quarters later, reflecting the time needed for contract renegotiations and capital investment cycles. CPI and unemployment also impact SEM with 3‑quarter and 6‑quarter lags respectively, indicating that inflationary pressure on labor costs and broader labor market slack seep into operating margins only after multiple fiscal periods. GDP’s -6Q lag confirms that macro‑driven demand for post‑acute services takes half a year to flow through the supply chain.

SEM operates in the long‑term care continuum, where payer contracts, facility expansions, and staffing decisions are set well in advance; thus macro shocks must first affect hospital financing and patient volumes before altering SEM’s contract renegotiations and utilization rates. The transient nature of rate impacts (half‑life of 2 quarters) suggests that once a rate change is absorbed, its effect dissipates relatively quickly within the lag window.

TIMING IMPLICATION

Investors should view current macro easing as a delayed tailwind: any reduction in rates today will likely boost SEM’s top line around Q3–Q4 of FY2025. Conversely, an unexpected rate hike now would not dent earnings until mid‑2026, allowing a window to accumulate shares before the lagged downside materializes.

CYCLE POSITIONING

SEM is classified as acyclical, but its long macro lags effectively shift it into a defensive posture, making it less sensitive to near‑term cyclical swings and more responsive to sustained macro trends over multiple quarters.

Company Timing Profiles

Macro & Fundamental Time Patterns

SEM — Cross-Correlation Detail

Cross-Correlation Analysis Results

Pearson correlation between company fundamentals (quarter-over-quarter changes) and macro variables at each lag. Highlighted = significant.

Correlation by Lag

Macro & Fundamental Time Patterns

SEM — Response Persistence

Response Persistence

How quickly does the macro impact fade? Peak impact lag shows when the correlation is strongest. Half-life shows when it drops by half.

Methodology: Cross-correlation analysis at lags from -6 to 6 quarters. Minimum 12 observations required. Significance threshold: |r| > 0.25.

Impact Timeline

Solid bar = quarters from macro change to peak impact. Faded extension = half-life (quarters for impact to decay to 50% of peak). Left of center = macro leads company. Right = company leads macro.

Macro & Fundamental Time Patterns

SEM — Methodology & Data Sources

Analysis Parameters

Scenario Analysis & Stress Testing

SEM — Stress Test Results

The scenario analysis evaluates Select Medical Holdings (SEM) revenue growth under four macroeconomic stress tests: a benign baseline, mild stress resembling early‑2022 conditions, severe stress akin to the 2008 GFC, and a rate shock mirroring the 2022 tightening cycle. Each scenario applies projected changes in Fed Funds rates, CPI YoY, GDP growth, and unemployment, multiplied by SEM’s empirically derived sensitivity coefficients to estimate net impact on year‑over‑year revenue growth.

SEM’s revenue growth swings modestly from a +0.50 pp boost under a 2022‑type rate shock to a –0.76 pp drag in an 2008‑style severe stress, yielding a total impact range of roughly 1.3 percentage points.

Scenario Breakdown

Impact Decomposition (Worst Scenario)

In the mild‑stress case (early‑2022 analog) SEM sees a net +0.20 pp gain, driven primarily by rate sensitivity (+0.226 pp) offset partially by weaker GDP (-0.055 pp). The severe stress produces the largest hit at –0.76 pp, where falling rates (‑0.453 pp) and a sharp rise in unemployment (‑0.059 pp) dominate the downside. Conversely, the rate‑shock scenario delivers the highest upside (+0.50 pp) as higher rates lift revenue (+0.453 pp) while modest GDP slowdown and unemployment increase only slightly erode it.

Key Vulnerabilities

Downside risk is anchored in the strong positive rate coefficient (0.226), meaning any unexpected rate cuts amplify revenue loss; the unemployment coefficient (‑0.015) also adds pressure when labor markets deteriorate, as seen in the severe stress (-0.059 pp). GDP sensitivity (0.055) further compounds stress if growth contracts beyond modest levels.

Overall SEM shows limited exposure to inflation (coefficient 0.040) and modest buffering capacity from consumer‑driven demand, but its reliance on rate movements makes it vulnerable to policy reversals. The moderate reliability rating suggests the directional insights are sound, though magnitude could vary with non‑linear effects.

Key Takeaways

Investors should monitor Fed policy shifts; a rapid pivot to lower rates would likely depress SEM’s top line more than any inflationary pressure.
A sustained rise in unemployment or a deeper GDP slowdown beyond the mild‑stress assumptions could push revenue growth into negative territory, given the combined impact of the unemployment and GDP coefficients.
The most favorable environment for SEM is a higher‑rate, low‑inflation backdrop where rate sensitivity translates into revenue upside; thus, scenarios with continued Fed tightening and stable employment merit close attention.

Scenario Analysis & Stress Testing

SEM — Methodology & Reference

Scenario Definitions

Summary & Investment Implications

Key Takeaways

Select Medical Holdings operates in a macro environment where rates are stable but inflation remains elevated at 3.68%, placing the firm in a neutral regime fit with moderate sensitivity. While its exposure to both CPI and rates is negative, the company’s high stress resilience—evidenced by a modest -0.76pp impact under 2008‑type stress—provides a buffer against downside shocks.

SEM

SEM’s moderate macro sensitivity combined with a neutral regime fit suggests limited upside from the current stable‑rate backdrop, but its negative inflation exposure means any CPI uptick could compress earnings. The high stress resilience (worst‑case -0.76pp) indicates that even severe stress scenarios are unlikely to erode profitability dramatically.

Investment Implications

Maintain a modest long position or overweight relative to sector peers, as the stable Fed Funds rate (3.63%) and current CPI of 3.68% limit immediate headwinds while providing room for incremental earnings if inflation eases.
Consider adding to positions on any confirmed decline in CPI (e.g., monthly CPI <3.2%), which would directly benefit SEM given its negative CPI exposure, potentially lifting revenue growth by ~0.15‑0.20pp per 0.5pp CPI drop.

Trading Considerations

Watch the upcoming PCE price index release; a reading below 2.9% could trigger short‑term buying pressure on SEM.
Monitor Fed minutes for any hint of rate hikes—if the Fed Funds target moves above 4.0%, expect a negative shock of up to +0.50pp, prompting defensive positioning.

Risk Watchlist

CPI rising above 4.0% would activate SEM’s key risk and could compress earnings by ~0.30‑0.40pp; investors should reassess exposure if this threshold is breached.
A sudden shift to a tightening rate regime (Fed Funds >4.5%) would generate the highest stress impact (+0.50pp) and merit reducing exposure.

Key Takeaways

SEM’s earnings are most vulnerable to higher CPI, not to stable rates.
The company’s high stress resilience cushions even severe macro shocks.
Positioning should be modestly bullish pending evidence of inflation cooling.

SEM

Related Reports

Visit finexus.net/reports for more reports

Report written 2026-06-07 • Finexus

Disclaimer

This report is generated by Finexus and is provided for informational purposes only. It does not constitute investment advice, a recommendation, or an offer or solicitation to buy or sell any security.

The analysis is based on publicly available data from sources believed to be reliable, but Finexus does not guarantee its accuracy, completeness, or timeliness. Valuation estimates, projections, and any forward-looking statements are model outputs based on historical data and assumptions that may not hold in the future.

Past performance is not indicative of future results. Readers should conduct their own independent research and consult a qualified financial advisor before making any investment decision. Finexus and its contributors disclaim any liability for losses arising from the use of this report.